When air sirens sound over Kyiv, Ukraine, patients undergoing bone marrow transplants at Ohmatdyt National Children’s Hospital don’t have the option of going to the bomb shelter.
Two decades after uncovering the role of EGFR mutations in lung cancer, scientists are still grappling with lingering research questions.
In 1998, lung cancer was the leading cause of cancer deaths in the United States, with 160,000 deaths per year. That statistic inspired Matthew Meyerson, who would soon start working at the Dana-Farber Cancer Institute, to specialize in lung cancer.
Edward Sondik, an electrical engineer by training, followed a career path that led him to top public health positions.He was a director of the National Center for Health Statistics at CDC, an acting director of NCI, and a deputy director of the NCI Division of Cancer Prevention and Control.
Edward Sondik, former director of the National Center for Health Statistics at CDC, who previously served as an acting director of NCI, and a deputy director of the NCI Division of Cancer Prevention and Control, died on June 25. He was 82.
Nathan Berger, professor of medicine, biochemistry, oncology, and genetics; the Hanna-Payne Professor of Experimental Medicine; the director of the Center for Science, Health, and Society; and a Distinguished University Professor at Case Western Reserve University, died on June 15. He was 83.
On Sept. 24, 2002, when I showed up at a meeting of the FDA Oncologic Drugs Advisory Committee, I had a pretty good idea that the drug on the agenda—AstraZeneca’s Iressa (gefitinib)—was having a surprising effect on some patients in third-line non-small cell lung cancer.
On Sept. 24, 2002, the Oncologic Drugs Advisory Committee recommended an accelerated approval for AstraZeneca’s Iressa (gefitinib). The recommendation concluded a meeting where ODAC weighed whether the drug, an EGFR tyrosine kinase inhibitor, could benefit patients with resistant or refractory non-small cell lung cancer as a third-line therapy.
Pharmacologist V. Craig Jordan, a professor of Breast and Medical Oncology and Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center who discovered selective estrogen receptor modulators and developed breakthrough breast cancer treatments, died June 9 at his home in Houston.
So far in 2024, 516 anti-queer bills have been introduced in state legislatures across the country, part of a coordinated effort where bills getting traction in one state are soon parroted by legislators in others.
